GT201700189A - Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos - Google Patents

Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos

Info

Publication number
GT201700189A
GT201700189A GT201700189A GT201700189A GT201700189A GT 201700189 A GT201700189 A GT 201700189A GT 201700189 A GT201700189 A GT 201700189A GT 201700189 A GT201700189 A GT 201700189A GT 201700189 A GT201700189 A GT 201700189A
Authority
GT
Guatemala
Prior art keywords
nucleosids
derivatives
antineoplastic agents
replaced
useful
Prior art date
Application number
GT201700189A
Other languages
English (en)
Inventor
John Howard Tatlock
Indrawan James Mcalpine
Michelle Bich Tran-Dube
Eugene Yuanjin Rui
Martin James Wythes
Robert Arnold Kumpf
Michele Ann Mctigue
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of GT201700189A publication Critical patent/GT201700189A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Abstract

LOS COMPUESTOS DE FÓRMULA GENERAL (I): PROCESOS PARA LA PREPARACIÓN DE ESTOS COMPUESTOS, COMPOSICIONES QUE CONTIENEN ESTOS COMPUESTOS Y LOS USOS DE ESTOS COMPUESTOS.
GT201700189A 2015-02-24 2017-08-24 Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos GT201700189A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562119932P 2015-02-24 2015-02-24
US201562213801P 2015-09-03 2015-09-03
US201662279209P 2016-01-15 2016-01-15

Publications (1)

Publication Number Publication Date
GT201700189A true GT201700189A (es) 2019-06-10

Family

ID=55451515

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201700189A GT201700189A (es) 2015-02-24 2017-08-24 Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos

Country Status (29)

Country Link
US (1) US10428104B2 (es)
EP (1) EP3262057B1 (es)
JP (1) JP6584521B2 (es)
KR (1) KR20170119705A (es)
CN (1) CN107278205A (es)
AU (2) AU2016225133B2 (es)
BR (1) BR112017017396A2 (es)
CA (1) CA2921314A1 (es)
CL (1) CL2017002155A1 (es)
CO (1) CO2017008403A2 (es)
CR (1) CR20170384A (es)
CU (1) CU20170105A7 (es)
DO (1) DOP2017000195A (es)
EA (1) EA031895B1 (es)
ES (1) ES2792899T3 (es)
GT (1) GT201700189A (es)
IL (1) IL253637A0 (es)
MX (1) MX2017010844A (es)
NI (1) NI201700095A (es)
PE (1) PE20171449A1 (es)
PH (1) PH12017501413A1 (es)
SG (1) SG11201706050WA (es)
SV (1) SV2017005514A (es)
TN (1) TN2017000357A1 (es)
TW (1) TWI622595B (es)
UA (1) UA118315C2 (es)
UY (1) UY36564A (es)
WO (1) WO2016135582A1 (es)
ZA (1) ZA201705092B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
KR20180116307A (ko) 2016-03-10 2018-10-24 얀센 파마슈티카 엔.브이. Prmt5 저해제로 사용하기 위한 치환 뉴클레오사이드 유사체
JP6909799B2 (ja) * 2016-03-10 2021-07-28 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤として使用するための置換ヌクレオシドアナログ
US10611778B2 (en) 2016-09-14 2020-04-07 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-MLL interaction
AU2017326487B2 (en) 2016-09-14 2021-08-05 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
EP3519413A1 (en) 2016-10-03 2019-08-07 Janssen Pharmaceutica NV Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
CA3044739A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
US11220524B2 (en) * 2017-02-20 2022-01-11 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
WO2018152501A1 (en) * 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
WO2018154104A1 (en) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US10570140B2 (en) * 2017-08-09 2020-02-25 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
WO2019084470A1 (en) * 2017-10-26 2019-05-02 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
BR112020010815A2 (pt) * 2017-12-08 2020-11-10 Janssen Pharmaceutica Nv análogos espirobicíclicos
PE20211444A1 (es) 2017-12-13 2021-08-05 Lupin Ltd Componentes heterociclicos biciclicos sustituidos como inhibidores de prmt5
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
FI3765461T3 (fi) * 2018-03-14 2023-11-13 Prelude Therapeutics Inc Proteiiniarginiinimetyylitransferaasi-5:n (prmt5) selektiivisiä estäjiä
EP3833669A4 (en) * 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
EP3924360A1 (en) * 2019-02-13 2021-12-22 Prelude Therapeutics, Incorporated Selective inhibitor of protein arginine methyltransferase 5 (prmt5)
WO2020198323A1 (en) * 2019-03-25 2020-10-01 California Institute Of Technology Prmt5 inhibitors and uses thereof
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
RS64972B1 (sr) 2019-06-10 2024-01-31 Lupin Ltd Inhibitori prmt5
BR112021024457A2 (pt) 2019-06-12 2022-01-18 Janssen Pharmaceutica Nv Intermediários espirobicíclicos
CN114599361A (zh) 2019-10-22 2022-06-07 印度鲁宾有限公司 Prmt5抑制剂的药物组合物
WO2021111322A1 (en) 2019-12-03 2021-06-10 Lupin Limited Substituted nucleoside analogs as prmt5 inhibitors
CR20230129A (es) 2020-08-18 2023-07-13 Incyte Corp Proceso e intermediarios para preparar un inhibidor de jak
EP4200278A1 (en) 2020-08-18 2023-06-28 Incyte Corporation Process and intermediates for preparing a jak1 inhibitor
WO2022074391A1 (en) * 2020-10-08 2022-04-14 Storm Therapeutics Limited Compounds inhibitors of mettl3
CN112679505B (zh) * 2020-12-25 2022-04-22 杭州澳赛诺生物科技有限公司 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
WO2023017152A1 (en) * 2021-08-13 2023-02-16 Albert-Ludwigs-Universität Freiburg Specific small molecule inhibitors that block kmt9 methyltransferase activity and function

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5864033A (en) * 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5795977A (en) * 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6831069B2 (en) * 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
JP4596913B2 (ja) * 2002-08-15 2010-12-15 ギリアード・パロ・アルト・インコーポレイテッド Ａ１アデノシン受容体の部分および完全アゴニスト
EP2408306A4 (en) * 2009-03-20 2012-11-07 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
US9416154B2 (en) * 2011-07-13 2016-08-16 Merck Sharp & Dohme Corp. 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US8575119B2 (en) * 2011-09-23 2013-11-05 Enanta Pharmaceuticals, Inc. 2′-chloroacetylenyl substituted nucleoside derivatives
EP3160477A4 (en) * 2014-06-25 2018-07-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
AU2016301188A1 (en) * 2015-08-06 2018-02-15 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents

Also Published As

Publication number Publication date
DOP2017000195A (es) 2017-10-15
TWI622595B (zh) 2018-05-01
WO2016135582A1 (en) 2016-09-01
AU2018278842A1 (en) 2019-01-03
TN2017000357A1 (en) 2019-01-16
EP3262057A1 (en) 2018-01-03
CU20170105A7 (es) 2017-10-05
PE20171449A1 (es) 2017-10-02
AU2016225133A1 (en) 2017-08-10
CO2017008403A2 (es) 2017-10-31
SG11201706050WA (en) 2017-09-28
JP6584521B2 (ja) 2019-10-02
TW201643176A (zh) 2016-12-16
US10428104B2 (en) 2019-10-01
ES2792899T3 (es) 2020-11-12
EA031895B1 (ru) 2019-03-29
NI201700095A (es) 2017-10-31
SV2017005514A (es) 2018-04-11
CL2017002155A1 (es) 2018-05-11
KR20170119705A (ko) 2017-10-27
UA118315C2 (uk) 2018-12-26
PH12017501413A1 (en) 2018-01-29
MX2017010844A (es) 2017-12-07
IL253637A0 (en) 2017-09-28
UY36564A (es) 2016-09-30
EP3262057B1 (en) 2020-04-15
EA201791563A1 (ru) 2018-01-31
ZA201705092B (en) 2019-06-26
CR20170384A (es) 2017-11-16
CA2921314A1 (en) 2016-08-24
BR112017017396A2 (pt) 2018-04-03
US20160244475A1 (en) 2016-08-25
JP2018510850A (ja) 2018-04-19
AU2016225133B2 (en) 2018-11-29
CN107278205A (zh) 2017-10-20

Similar Documents

Publication Publication Date Title
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CO2018013105A2 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
UY38070A (es) Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
DOP2018000270A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CR20170564A (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CU20180027A7 (es) DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
CO2018004581A2 (es) Compuestos de criptoficina y productos conjugados, y sus métodos de preparación
ECSP17069696A (es) Compuestos novedosos
CL2016002089A1 (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2017000151A1 (es) Derivados de piridona
CR20180181A (es) Nuevos derivados de imidazol[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP17063489A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida